JP5964752B2 - 癌の臨床転帰を予測する方法 - Google Patents

癌の臨床転帰を予測する方法 Download PDF

Info

Publication number
JP5964752B2
JP5964752B2 JP2012540103A JP2012540103A JP5964752B2 JP 5964752 B2 JP5964752 B2 JP 5964752B2 JP 2012540103 A JP2012540103 A JP 2012540103A JP 2012540103 A JP2012540103 A JP 2012540103A JP 5964752 B2 JP5964752 B2 JP 5964752B2
Authority
JP
Japan
Prior art keywords
il6st
normalized
level
rna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012540103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514058A (ja
Inventor
ビー． ベイカー，ジョフリ
ビー． ベイカー，ジョフリ
ティー． クローニン，モーリーン
ティー． クローニン，モーリーン
コリン，フランソア
リュー，メイ−ラン
Original Assignee
ジェノミック ヘルス， インコーポレイテッド
ジェノミック ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノミック ヘルス， インコーポレイテッド, ジェノミック ヘルス， インコーポレイテッド filed Critical ジェノミック ヘルス， インコーポレイテッド
Publication of JP2013514058A publication Critical patent/JP2013514058A/ja
Application granted granted Critical
Publication of JP5964752B2 publication Critical patent/JP5964752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012540103A 2009-11-23 2010-11-19 癌の臨床転帰を予測する方法 Active JP5964752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
US61/263,763 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016129697A Division JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法

Publications (2)

Publication Number Publication Date
JP2013514058A JP2013514058A (ja) 2013-04-25
JP5964752B2 true JP5964752B2 (ja) 2016-08-03

Family

ID=44060376

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2012540103A Active JP5964752B2 (ja) 2009-11-23 2010-11-19 癌の臨床転帰を予測する方法
JP2016129697A Pending JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法
JP2018145578A Active JP7042717B2 (ja) 2009-11-23 2018-08-02 癌の臨床転帰を予測する方法
JP2020218527A Pending JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法
JP2022123265A Pending JP2022166064A (ja) 2009-11-23 2022-08-02 癌の臨床転帰を予測する方法
JP2022129605A Pending JP2022169647A (ja) 2009-11-23 2022-08-16 癌の臨床転帰を予測する方法
JP2023213416A Pending JP2024037948A (ja) 2009-11-23 2023-12-18 癌の臨床転帰を予測する方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2016129697A Pending JP2016214245A (ja) 2009-11-23 2016-06-30 癌の臨床転帰を予測する方法
JP2018145578A Active JP7042717B2 (ja) 2009-11-23 2018-08-02 癌の臨床転帰を予測する方法
JP2020218527A Pending JP2021058207A (ja) 2009-11-23 2020-12-28 癌の臨床転帰を予測する方法
JP2022123265A Pending JP2022166064A (ja) 2009-11-23 2022-08-02 癌の臨床転帰を予測する方法
JP2022129605A Pending JP2022169647A (ja) 2009-11-23 2022-08-16 癌の臨床転帰を予測する方法
JP2023213416A Pending JP2024037948A (ja) 2009-11-23 2023-12-18 癌の臨床転帰を予測する方法

Country Status (13)

Country Link
US (4) US20110123990A1 (enExample)
EP (4) EP3739060A1 (enExample)
JP (7) JP5964752B2 (enExample)
AU (1) AU2010321829B2 (enExample)
CA (2) CA3043089A1 (enExample)
DK (1) DK2504451T3 (enExample)
ES (1) ES2735993T3 (enExample)
HU (1) HUE044374T2 (enExample)
IL (5) IL219051A (enExample)
MX (3) MX391499B (enExample)
NZ (1) NZ599194A (enExample)
PL (1) PL2504451T3 (enExample)
WO (1) WO2011063274A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
PL1836629T3 (pl) * 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
MX2010014280A (es) * 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con metástasis y método para utilizarlos.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP3739060A1 (en) * 2009-11-23 2020-11-18 Genomic Health, Inc. Methods to predict clinical outcome of cancer
DK3178944T3 (da) 2010-01-11 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP2013532482A (ja) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いた前立腺癌の予後を定量化する方法
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
JP2014509868A (ja) * 2011-03-26 2014-04-24 オレゴン ヘルス アンド サイエンス ユニバーシティー 癌の予後のための遺伝子発現予測因子
WO2012178087A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
AU2012281152B2 (en) * 2011-07-13 2017-09-07 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
KR20140057331A (ko) * 2011-08-16 2014-05-12 온코사이트 코포레이션 유방암의 치료 및 진단을 위한 방법 및 조성물
CA2854805C (en) * 2011-11-08 2021-04-27 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
CN104662166A (zh) * 2012-04-20 2015-05-27 纪念斯隆-凯特琳癌症中心 与转移性乳腺癌相关的基因表达图谱
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
EP2920322B1 (en) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
CA2903878C (en) * 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US10392667B2 (en) * 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
EP3368686A1 (en) 2015-10-30 2018-09-05 Exact Sciences Development Company, LLC Multiplex amplification detection assay and isolation and detection of dna from plasma
CA3008273A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
SG11201901466PA (en) 2016-09-07 2019-03-28 Agency Science Tech & Res A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018140781A1 (en) 2017-01-27 2018-08-02 Exact Sciences Development Company, Llc Detection of colon neoplasia by analysis of methylated dna
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
CN114023403A (zh) 2017-11-13 2022-02-08 多发性骨髓瘤研究基金会公司 综合、分子、组学、免疫疗法、代谢、表观遗传学和临床数据库
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US11198911B2 (en) * 2018-03-08 2021-12-14 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
WO2020059850A1 (ja) * 2018-09-21 2020-03-26 国立大学法人東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
AU2019392939A1 (en) * 2018-12-08 2021-06-24 Decipher Biosciences, Inc. Transcriptomic profiling for prognosis of breast cancer
KR102449386B1 (ko) * 2019-05-03 2022-10-05 주식회사 디시젠 암 예후 예측방법 및 이의 조성물
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CA3210972A1 (en) * 2021-02-12 2022-08-18 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500832A (ja) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP2241636A1 (en) * 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2558808A1 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
WO2006037485A2 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
EP1863930A2 (en) * 2005-04-01 2007-12-12 NCC Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
JP2010524456A (ja) * 2007-04-16 2010-07-22 イプソゲン 乳癌に罹患している雌哺乳動物に対する臨床転帰の傾向を評価する方法
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
EP2568053B1 (en) * 2008-05-12 2014-04-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
EP3739060A1 (en) * 2009-11-23 2020-11-18 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
US20190241967A1 (en) 2019-08-08
US20110123990A1 (en) 2011-05-26
JP2013514058A (ja) 2013-04-25
PL2504451T3 (pl) 2019-09-30
US20210062275A1 (en) 2021-03-04
EP4350001A2 (en) 2024-04-10
JP2021058207A (ja) 2021-04-15
IL219051A0 (en) 2012-06-28
EP3556867A1 (en) 2019-10-23
DK2504451T3 (da) 2019-08-05
MX2012005822A (es) 2012-06-19
JP2016214245A (ja) 2016-12-22
EP4350001A3 (en) 2024-06-19
CA2776751A1 (en) 2011-05-26
MX391499B (es) 2025-03-21
MX2019003811A (es) 2019-08-05
JP7042717B2 (ja) 2022-03-28
WO2011063274A2 (en) 2011-05-26
MX363817B (es) 2019-04-04
IL219051A (en) 2016-12-29
NZ599194A (en) 2014-07-25
CA3043089A1 (en) 2011-05-26
CA2776751C (en) 2019-07-02
EP2504451A2 (en) 2012-10-03
WO2011063274A3 (en) 2014-03-27
JP2022169647A (ja) 2022-11-09
IL276487B (en) 2022-03-01
AU2010321829B2 (en) 2015-07-30
JP2024037948A (ja) 2024-03-19
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
IL249159A0 (en) 2017-01-31
IL264072A (en) 2019-02-28
ES2735993T3 (es) 2019-12-23
IL276487A (en) 2020-09-30
AU2010321829A1 (en) 2012-05-03
US20170211154A1 (en) 2017-07-27
JP2018196385A (ja) 2018-12-13
EP2504451A4 (en) 2016-07-06
EP2504451B1 (en) 2019-06-05
IL264072B (en) 2020-08-31
JP2022166064A (ja) 2022-11-01
MX337650B (es) 2016-03-14
EP3739060A1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
JP7042717B2 (ja) 癌の臨床転帰を予測する方法
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP6147755B2 (ja) 乳癌の予後を予測する方法
JP7301798B2 (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
EP3178944A2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP7239477B2 (ja) 前立腺がんにおける後期臨床エンドポイントを評価するためのアルゴリズムおよび方法
WO2015066068A1 (en) Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk
WO2014130617A1 (en) Method of predicting breast cancer prognosis
WO2014130444A1 (en) Method of predicting breast cancer prognosis
HK40014990A (en) Methods to predict clinical outcome of cancer
HK40052881A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
AU2017216545A1 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
HK1223132B (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
NZ711680B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160630

R150 Certificate of patent or registration of utility model

Ref document number: 5964752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250